Background: Insulin-like growth factor binding protein-4 (IGFBP-4), a member of the insulin-like growth factor (IGF) family, transports, and regulates the activity of IGFs. The pregnancy-associated plasma protein-A (PAPP-A) has proteolytic activity towards IGFBP-4, and both proteins have been associated with a variety of cancers, including lung cancer. Thus, we aimed to evaluate the use of IGFBP-4 and PAPP-A as potential biomarkers for lung cancer. Methods: Eighty-three volunteers, including 60 patients with lung cancer and 23 healthy individuals, were included in this study. The patients with lung cancer were selected based on their treatment status, histological subgroup, and stage of the disease. Enzyme-linked immunosorbent assays were used to assess the serum levels of IGFBP-4 and PAPPA, whereas the IGF-1 levels were measured using a chemiluminescent immunometric assay. Results: The serum IGFBP-4 levels in all patient groups, regardless of the treatment status and histological differences, were significantly higher than those in the control group (p<0.005). However, the serum PAPP-A levels in the untreated patient group were found to be higher than those in the control group, but this difference was not statistically significant (p=0.086). Conclusions: The serum PAPP-A and IGFBP-4 levels are elevated in lung cancer. However, IGFBP-4 may have better potential than PAPP-A as a lung cancer biomarker.
Uvod: Vezujući protein 4 (IGFBP-4), član porodice insulinu sličnih faktora rasta (IGF), prenosi i reguliše njihovu aktivnost. Plazma protein A u vezi trudnoće (PAPP-A) ima proteolitičku aktivnost prema IGFBP-4, a oba proteina su povezana sa različitim vrstama raka, uključujući karcinom pluća. Stoga smo želeli da procenimo upotrebu IGFBP-4 i PAPP-A kao potencijalnih biomarkera za karcinom pluća. Metode: U istraživanje je uključeno 83 dobrovoljnih učesnika, uključujući 60 pacijenata sa karcinomom pluća i 23 zdrave osobe. Pacijenti sa karcinomom pluća odabrani su na osnovu njihovog statusa lečenja, histološke podgrupe i stadijuma bolesti. Enzimski imunosorbentni testovi korišćeni su za procenu nivoa seruma vezujućeg proteina 4 i plazma proteina A, dok su nivoi IGF-1 mereni korišćenjem hemiluminescentnog imunometrijskog testa. Rezultati: Nivoi seruma IGFBP-4 u svim grupama pacijenata, bez obzira na status lečenja i histološke razlike, bili su značajno viši od onih u kontrolnoj grupi (p<0,005). Međutim, nađeno je da su nivoi seruma PAPP-A u nelečenoj grupi pacijenata viši od onih u kontrolnoj grupi, ali TA razlika nije bila statistički značajna (p=0,086). Zaključak: Serumski nivoi PAPP-A i IGFBP-4 povišeni su kod karcinoma pluća. Međutim, IGFBP-4 može imati bolji potencijal od PAPP-A kao biomarker raka pluća.
Keywords: IGF-1; IGFBP-4; PAPP-A; biomarkers; lung cancer.
2021 Savas Irem Nur, Akin Ozturk, Murat Kavas, Ismet Bulut, Sumeyye Alparslan, Eroglu Selma Aydogan, Baytemir Cansel Atinkaya, Murat Kolay, Abdurrahman Coskun, published by CEON/CEES.